PUBLIC COMPANY
saveAvidity Biosciences Inc
updated 3mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
2
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 22Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Novartis projects slowed growth, pins hopes on billions in pipeline potentialWith Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.biospace · 5h ago
- 9 biotechs will cut at least half their California workforcesWorkforce reductions have hit over 1,000 biopharma employees in The Golden State year to date, with pink slips coming from small biotechs and large pharmas. Biotechs have been hit the hardest, with…biospace · 16h ago
- Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustmentDespite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.fiercebiotech · 17h ago
- STAT+: PepGen says early trial for muscular dystrophy drug looks promisingPepGen says its candidate is correcting more of the genetic stutter found in myotonic dystrophy type 1.stat · 9d ago
- Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivalsFull data from the Phase 3 HORIZON trial of Novartis' pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as A…biospace · 10d ago
- Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting gameLilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.biopharma_dive · 20d ago
- Lilly shuffles business structure; Novartis writes off part of Avidity dealLilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.biopharma_dive · 22d ago
- Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buyNovartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.biospace · 23d ago
- After $1.9B impairment hit, Novartis stands by $12B bet on AvidityNovartis’ $12 billion acquisition of Avidity Biosciences “remains absolutely on track,” CEO Vas Narasimhan said, after the company disclosed a $1.9 billion impairment charge on a failed late-stage…endpoints · 23d ago
- Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran failNovartis CEO Vas Narasimhan has insisted that the phase 3 fail for del-desiran is just a “bump” in the Swiss pharma’s wider plans for the drug, despite costing the company an estimated $1.9 billion.fiercebiotech · 23d ago
comments(0)
5-min edit window · permanent after that